LetterKeratoacanthomas associated with sorafenib therapy
References (4)
- ClinicalTrials.gov [database online]. Bethesda, MD: National Library of Medicine; 2006. Available at:...
- et al.
Raf kinase inhibitors in oncology
Onkologie
(2005)
Cited by (85)
Emergence of ocular toxicities associated with novel anticancer therapeutics: What the oncologist needs to know
2022, Cancer Treatment ReviewsCitation Excerpt :Sunitinib has been associated with retinal detachments (at least 24 cases) [54]. Sorafenib is associated with squamoproliferative lesions, such as keratoacanthomas, and squamous cell carcinoma affecting the eyelid [55], retinal detachments (at least 7 reported cases), and retinal tears (at least 2 reported cases) in case reports [54,56]. Management: Periorbital edema from imatinib is typically mild and can be managed conservatively.
Anticancer therapies associated with secondary cutaneous malignancies: A review of the literature
2020, Journal of the American Academy of DermatologyCitation Excerpt :This dose-dependent BRAF inhibitor–induced cutaneous toxicity substantiates the rates of SCM across the classes of drugs sharing this mechanism.13 Since 2006, when Lacouture et al35 reported the first cases of MKI-induced SCM, multiple publications have described a wide spectrum of squamoproliferative lesions,36-39 including follicular infundibular ectasia, inflamed actinic keratoses, KAs, and invasive cSCC.36 An association between MKIs and secondary BCCs has also been suggested, but no adequate mechanisms have been determined.
Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane
2015, Journal of the American Academy of DermatologyFármacos antiangiogénicos y piel: Efectos cutáneos adversos de sorafenib, sunitinib y bevacizumab
2014, Actas Dermo-SifiliograficasCutaneous toxicities of BRAF inhibitors: Clinical and pathological challenges and call to action
2013, Critical Reviews in Oncology/HematologyTargeted therapy in melanoma
2013, Clinics in DermatologyCitation Excerpt :It has been reported to have the microscopic appearance of a lobular, neutrophilic panniculitis. A variety of other side effects, such as xerosis, keratosis pilaris (Figure 5), pruritus, paronychia, alopecia mimicking androgenic alopecia, and a change in hair texture to a “strawlike,” dry, and fine consistency83-87 have been reported. Localized or diffuse hyper- or hypopigmentation have also frequently been reported.89